Press releaseGlobe Newswire
Veraxa Biotech AG
VRXA · NASDAQ
$1.01+$0.01 (+1.00%)TodayMarket closed ·
Prev close $1.00
Latest news
- Press releaseGlobe Newswire
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- News
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan
- Press releaseGlobe Newswire
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
- NewsAvi Kapoor
FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Monday
- NewsAvi Kapoor
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday
- News
Veraxa Biotech Initiated Cell Line Development For Its Lead BiTAC T-cell Engager Program
- Press releaseGlobe Newswire
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Crude Oil Down Over 3%; US Consumer Sentiment Rises In June
- Press releaseGlobe Newswire
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.